BioXcel Therapeutics announced that it has regained compliance with the Nasdaq Capital Market's market value of listed securities (MVLS) requirement. The company received written notice from Nasdaq confirming its compliance with Listing Rule 5550(b)(2).
The company had previously been notified on March 20, 2025, that its MVLS was below $35.0 million for 30 consecutive business days. Following a hearing on May 1, 2025, the Nasdaq Hearings Panel granted an exception, providing the company until September 16, 2025, to regain compliance.
Nasdaq delivered a notice on September 17, 2025, confirming that BioXcel Therapeutics had regained compliance with the MVLS Rule. With this resolution, the company now meets all Nasdaq Capital Market listing requirements for continued listing, and this matter is officially closed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.